The University of Southampton
University of Southampton Institutional Repository

Galectin-3 is a natural binding ligand of MCAM (CD146, MUC18) in melanoma cells and their interaction promotes melanoma progression

Galectin-3 is a natural binding ligand of MCAM (CD146, MUC18) in melanoma cells and their interaction promotes melanoma progression
Galectin-3 is a natural binding ligand of MCAM (CD146, MUC18) in melanoma cells and their interaction promotes melanoma progression

Melanoma cell adhesion molecule (MCAM, CD146, MUC18) is a heavily glycosylated transmembrane protein and a marker of melanoma metastasis. It is expressed in advanced primary melanoma and metastasis but rarely in benign naevi or normal melanocytes. More and more evidence has shown that activation of the MCAM on cell surface plays a vital role in melanoma progression and metastasis. However, the natural MCAM binding ligand that initiates MCAM activation in melanoma so far remains elusive. This study revealed that galectin-3, a galactoside-binding protein that is commonly overexpressed in many cancers including melanoma, is naturally associated with MCAM on the surface of both skin and uveal melanoma cells. Binding of galectin-3 to MCAM, via O-linked glycans on the MCAM, induces MCAM dimerization and clustering on cell surface and subsequent activation of downstream AKT signalling. This leads to the increases of a number of important steps in melanoma progression of cell proliferation, adhesion, migration, and invasion. Thus, galectin-3 is a natural binding ligand of MCAM in melanoma, and their interaction activates MCAM and promotes MCAM-mediated melanoma progression. Targeting the galectin-3–MCAM interaction may potentially be a useful therapeutic strategy for melanoma treatment.

MCAM/CD146, cancer, galectin-3, galectin–ligand interaction, melanoma
Pang, Yaoyu
dac2b079-8ad3-4468-a2f3-ba36ed86e818
Maxwell, Ellen
7c8c7514-a2e3-4003-a488-0f2c0937cb34
Sindrewicz-Goral, Paulina
6eae95da-9e41-40c7-aad3-c59d1854492b
Shapanis, Andrew
98b07884-92a9-4c00-afad-12194e339cbc
Li, Shun
f462fe35-203f-4b2a-a81c-edf6dd11f126
Morgan, Mark
5724cc5e-c92e-4055-9165-a60e81b27123
Yu, Lu-Gang
40d70721-86c1-44d5-ac48-0f6091e7a233
Pang, Yaoyu
dac2b079-8ad3-4468-a2f3-ba36ed86e818
Maxwell, Ellen
7c8c7514-a2e3-4003-a488-0f2c0937cb34
Sindrewicz-Goral, Paulina
6eae95da-9e41-40c7-aad3-c59d1854492b
Shapanis, Andrew
98b07884-92a9-4c00-afad-12194e339cbc
Li, Shun
f462fe35-203f-4b2a-a81c-edf6dd11f126
Morgan, Mark
5724cc5e-c92e-4055-9165-a60e81b27123
Yu, Lu-Gang
40d70721-86c1-44d5-ac48-0f6091e7a233

Pang, Yaoyu, Maxwell, Ellen, Sindrewicz-Goral, Paulina, Shapanis, Andrew, Li, Shun, Morgan, Mark and Yu, Lu-Gang (2022) Galectin-3 is a natural binding ligand of MCAM (CD146, MUC18) in melanoma cells and their interaction promotes melanoma progression. Biomolecules, 12 (10), [1451]. (doi:10.3390/biom12101451).

Record type: Article

Abstract

Melanoma cell adhesion molecule (MCAM, CD146, MUC18) is a heavily glycosylated transmembrane protein and a marker of melanoma metastasis. It is expressed in advanced primary melanoma and metastasis but rarely in benign naevi or normal melanocytes. More and more evidence has shown that activation of the MCAM on cell surface plays a vital role in melanoma progression and metastasis. However, the natural MCAM binding ligand that initiates MCAM activation in melanoma so far remains elusive. This study revealed that galectin-3, a galactoside-binding protein that is commonly overexpressed in many cancers including melanoma, is naturally associated with MCAM on the surface of both skin and uveal melanoma cells. Binding of galectin-3 to MCAM, via O-linked glycans on the MCAM, induces MCAM dimerization and clustering on cell surface and subsequent activation of downstream AKT signalling. This leads to the increases of a number of important steps in melanoma progression of cell proliferation, adhesion, migration, and invasion. Thus, galectin-3 is a natural binding ligand of MCAM in melanoma, and their interaction activates MCAM and promotes MCAM-mediated melanoma progression. Targeting the galectin-3–MCAM interaction may potentially be a useful therapeutic strategy for melanoma treatment.

Text
biomolecules-12-01451 - Version of Record
Available under License Creative Commons Attribution.
Download (2MB)

More information

Accepted/In Press date: 7 October 2022
Published date: 10 October 2022
Additional Information: Funding Information: YP was supported by a University of Liverpool PhD studentship. PSG was supported by an MRC Industrial Case studentship (MR/L014327). Publisher Copyright: © 2022 by the authors.
Keywords: MCAM/CD146, cancer, galectin-3, galectin–ligand interaction, melanoma

Identifiers

Local EPrints ID: 472477
URI: http://eprints.soton.ac.uk/id/eprint/472477
PURE UUID: 6967cad2-0923-4bcf-9458-52e8d33e5346
ORCID for Andrew Shapanis: ORCID iD orcid.org/0000-0003-4147-6956

Catalogue record

Date deposited: 06 Dec 2022 17:38
Last modified: 17 Mar 2024 03:58

Export record

Altmetrics

Contributors

Author: Yaoyu Pang
Author: Ellen Maxwell
Author: Paulina Sindrewicz-Goral
Author: Andrew Shapanis ORCID iD
Author: Shun Li
Author: Mark Morgan
Author: Lu-Gang Yu

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×